Literature DB >> 12883879

Loss of heterozygosity and methylation of p16 in renal cell carcinoma.

M T Sanz-Casla1, M L Maestro, V del Barco, I Zanna, J Moreno, M Vidaurreta, I Almansa, C Fernández, J Blanco, C Maestro, L Resel.   

Abstract

To investigate the possible role of genomic aberrations of chromosome 9p21 in the tumorigenesis of human renal cell carcinoma (RCC), 40 sporadic RCCs were studied using PCR analyses. The tumours were predominantly low stage and low grade. Loss of heterozygosity (LOH) was observed in nine of 39 informative cases, but no homozygous deletion was noticed. Hypermethylation of the promoter region of p16 occurred in eight of the 40 RCCs. No correlation was found between hypermethylation of the p16 gene and LOH on 9p21. A similar level of LOH and methylation was observed in the 40 RCCS regardless of histology, grade and stage. These results suggest that inactivation of p16 and the possibility of other unknown tumour suppressor genes located on other chromosomes could be involved in the pathogenesis of RCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883879     DOI: 10.1007/s00240-003-0308-3

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  24 in total

1.  Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer.

Authors:  S K Kim; J Y Ro; B L Kemp; J S Lee; T J Kwon; K M Fong; Y Sekido; J D Minna; W K Hong; L Mao
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

2.  Allelotype of renal cell carcinoma.

Authors:  R Morita; J Ishikawa; M Tsutsumi; K Hikiji; Y Tsukada; S Kamidono; S Maeda; Y Nakamura
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

3.  Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.

Authors:  C Maesawa; G Tamura; S Nishizuka; S Ogasawara; K Ishida; M Terashima; K Sakata; N Sato; K Saito; R Satodate
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

4.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Authors:  M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

5.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.

Authors:  J F Costello; M S Berger; H S Huang; W K Cavenee
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

7.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.

Authors:  J Q Cheng; S C Jhanwar; W M Klein; D W Bell; W C Lee; D A Altomare; T Nobori; O I Olopade; A J Buckler; J R Testa
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

8.  Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas.

Authors:  P Cairns; K Tokino; Y Eby; D Sidransky
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

10.  Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.

Authors:  G M Maelandsmo; J M Berner; V A Flørenes; A Forus; E Hovig; O Fodstad; O Myklebost
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more
  8 in total

Review 1.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

2.  5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.

Authors:  H Hagiwara; H Sato; Y Ohde; Y Takano; T Seki; T Ariga; N Hokaiwado; M Asamoto; T Shirai; Y Nagashima; T Yano
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

3.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

4.  Alterations of the WNT7A gene in clear cell renal cell carcinomas.

Authors:  Aleksandr G Kondratov; Sergiy M Kvasha; Liubov A Stoliar; Alina M Romanenko; Yury M Zgonnyk; Vasily V Gordiyuk; Elena V Kashuba; Alla V Rynditch; Eugene R Zabarovsky; Vladimir I Kashuba
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

5.  Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.

Authors:  Mark R Morris; Eamonn R Maher
Journal:  Genome Med       Date:  2010-09-03       Impact factor: 11.117

6.  Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.

Authors:  Qianling Liu; Jie Jin; Jianming Ying; Mengkui Sun; Yun Cui; Lian Zhang; Ben Xu; Yu Fan; Qian Zhang
Journal:  Int J Mol Sci       Date:  2015-05-11       Impact factor: 5.923

7.  Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.

Authors:  I El-Mokadem; J Fitzpatrick; J Bondad; P Rauchhaus; J Cunningham; N Pratt; S Fleming; G Nabi
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

8.  Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: a meta-analysis.

Authors:  Yu Ren; Li Xiao; Guobin Weng; Bingyi Shi
Journal:  Oncotarget       Date:  2017-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.